The prognosis of glioblastoma, the most malignant type of glioma, is still poor, with only a minority of patients showing long-term survival of more than three years after diagnosis. To elucidate the molecular aberrations in glioblastomas of long-term survivors, we performed genome- and/or transcriptome-wide molecular profiling of glioblastoma samples from 94 patients, including 28 long-term survivors with >36 months overall survival (OS), 20 short-term survivors with
Prof. Dr. G. Reifenberger
Corresponding Author Institution
Department of Neuropathology
Heinrich Heine University
Corresponding Author email
Int J Cancer.
German Cancer Aid (Deutsche Krebshilfe); Grant number: 70-3163-Wi 3